Ed­i­tas’ ri­vals ap­peal a re­cent set­back on patent fight, map­ping a glob­al war for CRISPR su­prema­cy

The gene edit­ing con­sor­tium that has sought to bot­tle up ri­val Ed­i­tas $ED­IT with claims of patent in­fringe­ment are mak­ing a fed­er­al case out of a re­cent set­back in the US.

In mid-Feb­ru­ary the US Patent Tri­al and Ap­peal Board ruled that there was no in­ter­fer­ence be­tween the two sides in the dis­pute, al­low­ing each to patent their work on CRISPR/Cas9 and car­ry on. But the Uni­ver­si­ty of Cal­i­for­nia, the Uni­ver­si­ty of Vi­en­na, and Dr. Em­manuelle Char­p­en­tier aren’t tak­ing no for an an­swer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER